Your browser doesn't support javascript.
loading
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment ; : 737-747, 2019.
Artigo em Inglês | WPRIM | ID: wpr-763122
ABSTRACT

PURPOSE:

We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance. MATERIALS AND

METHODS:

A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.

RESULTS:

In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).

CONCLUSION:

A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.
Assuntos

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Fenobarbital / Mama / Neoplasias da Mama / Imuno-Histoquímica / Classificação / Hibridização In Situ / Genes Neoplásicos / Neoplasias de Mama Triplo Negativas / Receptores ErbB / Fluorescência Tipo de estudo: Guia de Prática Clínica / Estudo prognóstico Limite: Humanos Idioma: Inglês Revista: Cancer Research and Treatment Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Fenobarbital / Mama / Neoplasias da Mama / Imuno-Histoquímica / Classificação / Hibridização In Situ / Genes Neoplásicos / Neoplasias de Mama Triplo Negativas / Receptores ErbB / Fluorescência Tipo de estudo: Guia de Prática Clínica / Estudo prognóstico Limite: Humanos Idioma: Inglês Revista: Cancer Research and Treatment Ano de publicação: 2019 Tipo de documento: Artigo